Friday, 03 March 2023 at 13:00 UK (14:00 CET) Register here Okke has created many business solutions, set up centers of excellence around the globe and trained many researchers and clients on advanced analytical techniques. He is a client facing statistician as he believes that direct work with client is the best way to […]
Dear clients and colleagues, As before this year’s budget that used to be for physical Christmas mailings to three selected organisations who do incredible work throughout the year in different areas. They were not chosen for their size but for how close we feel to their cause, how they are run, how well we know […]
ephmra is delighted to host Professor Paul Goodwin Emeritus Professor and renowned speaker in Forecasting and Decision Analysis, on November 11th at 1:00 UK pm at the ephmra Forecasting Forum. Prof. Goodwin will introduce the topic of Possibility Theory/Fuzzy Forecasting to the ephmra audience for discussion. Chair of the event @Erik Holzinger/groupH To join, please […]
Join our discussion on Forecasting Best Practices Across Product Stages hosted by the NPP Community on Wednesday, November 2nd 2022, at 15.00 CET. Unique opportunity to meet and talk to @Erik Holzinger/groupH and @Morris Paterson/Genentech. To join the event please follow: https://lnkd.in/eHZ3Hw2w
groupH’s director, Erik Holzinger, will be attending BIO-Europe – starting by joining BiotechBikers event and Sunday’s Networking Reception. If you wish to discuss partnering or business opportunities in early to mid-stage commercial decision-making and product development, please email erik.holzinger@grouph.com or use the event’s partneringOne platform to arrange a meeting. We look forward to meeting with […]
Realistic net-prices and peak-patient-shares are key requirements for providing early commercial direction for assets whose clinical profile might not yet been finalised. Early to mid-stage commercial decision-making benefits from specialised tools that have been specifically developed for this purpose. During the past year groupH developed an evidence-based Peak-Patient-Share tool (a.k.a. the Devil’s Advocate Tool) that […]
